Published in Int J Mol Sci on November 17, 2015
The making of bispecific antibodies. MAbs (2017) 0.84
Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies. Cancer Lett (2017) 0.75
Detection of a phosphorylated glycine-serine linker in an IgG-based fusion protein. MAbs (2016) 0.75
FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol (2007) 7.94
Convergent solutions to binding at a protein-protein interface. Science (2000) 4.47
Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity. Proc Natl Acad Sci U S A (2000) 2.63
Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res (2009) 2.58
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol (2007) 2.53
Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol (2000) 2.25
An efficient route to human bispecific IgG. Nat Biotechnol (1998) 1.93
How antibodies fold. Trends Biochem Sci (2009) 1.88
Biophysical properties of human antibody variable domains. J Mol Biol (2003) 1.80
PK modulation of haptenylated peptides via non-covalent antibody complexation. J Control Release (2013) 1.46
Bispecific antibodies. Drug Discov Today (2015) 1.44
Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res (2011) 1.42
Kabat database and its applications: 30 years after the first variability plot. Nucleic Acids Res (2000) 1.36
Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res (2008) 1.35
Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs (2012) 1.29
High throughput thermostability screening of monoclonal antibody formulations. J Pharm Sci (2010) 1.19
Bispecific digoxigenin-binding antibodies for targeted payload delivery. Proc Natl Acad Sci U S A (2011) 1.15
Disulfide stabilization of antibody Fv: computer predictions and experimental evaluation. Protein Eng (1995) 1.10
Development of secreted proteins as biotherapeutic agents. Expert Opin Biol Ther (2004) 1.06
Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer. Cancer Genomics Proteomics (2014) 1.04
Complex and defined biostructures with the dock-and-lock method. Trends Pharmacol Sci (2012) 0.93
Pretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistry. Front Med (Lausanne) (2014) 0.92
Complement recruitment using bispecific diabodies. Nat Biotechnol (1997) 0.87
Developability assessment during the selection of novel therapeutic antibodies. J Pharm Sci (2015) 0.87
Hapten-directed spontaneous disulfide shuffling: a universal technology for site-directed covalent coupling of payloads to antibodies. FASEB J (2015) 0.87
Tumor-antigen-binding bispecific antibodies for cancer treatment. Semin Oncol (2014) 0.86
Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptor. MAbs (2014) 0.84
Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing. Protein Eng Des Sel (2012) 0.83
Targeted siRNA Delivery and mRNA Knockdown Mediated by Bispecific Digoxigenin-binding Antibodies. Mol Ther Nucleic Acids (2012) 0.79
Mechanical stability of the antibody domain CH3 homodimer in different oxidation states. J Am Chem Soc (2013) 0.78